Foliglurax
| |
Clinical data | |
---|---|
Synonyms | DT-1687; PXT-002331; PXT-2331 |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C23H23N3O3S |
Molar mass | 421.515 g/mol |
3D model (JSmol) | |
| |
|
Foliglurax (developmental code names PXT-002331, DT-1687) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4) which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[1][2] As of July 2017, it is in phase II clinical trials for this indication.[1]
References
- 1 2 http://adisinsight.springer.com/drugs/800044176
- ↑ Ellis, J. Michael; Fell, Matthew J. (2017). "Current approaches to the treatment of Parkinson's Disease". Bioorganic & Medicinal Chemistry Letters. doi:10.1016/j.bmcl.2017.07.075. ISSN 0960-894X.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.